NCQA: Accelerating Health Equity Outcomes

From the National Committee for Quality Assurance (NCQA) Health Equity Director Bryan O. Buckley DrPH, MPH joins the podcast to share his story and efforts to progress health equity for disadvantaged families across the US.

NCQA is committed to evolving equity in healthcare through services, programs and next generation accreditations aimed at supporting Health Plans, Healthcare, Government and Employers.

On this episode we discuss…

  1. NCQA’s programs that outline how healthcare professionals can improve equity at practices and clinics
  2. The evolution of health equity and why equity is vital to the healthcare ecosystem
  3. How the team at NCQA organizes and reaches their goals

“Think of it like a Justice League. We have so many superheroes involved within our company. Look at them as the health equity champions to help coalesce the work that’s being done in each unit or division, and that in many ways is how we build up our team. Don’t think of it so much as a team, but I like to think of myself as the watchtower really helping to be a space for people to co-collaborate, talk shop, talk about the challenges that we see from different stakeholders and also think about who do we need to partner with, who’s missing at the table and so forth. And so that would be how I define the health equity team. It’s many different people involved in many different departments, really building on that collective intelligence we all need to truly make health equity sustain itself moving forward,” said Buckley.

Dr. Bryan Buckley is a healthcare professional and researcher and is also the Director of Health Equity Initiatives at the National Committee for Quality Assurance. Buckley started his career in equity in public health and is a graduate of the Harvard T.H. Chan School of Public Health and Michigan State University.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…